We have shown the ability of the ApoB peptide (ApoB11) to transport an ASO sequence targeted to aSyn for a systemic therapy for synucleinopathies that has proven effective in synucleinopathy models of Parkinson’s disease and Dementia with Lewy Bodies [12, 24]. Here, APOB is linked to synucleinopathy.